L'asse c-Myc-USP14-PFKP sostiene la chemioresistenza nel carcinoma adenocarcinomatoso pancreatico.

BACKGROUND: Therapeutic resistance remains a major clinical challenge in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence indicates that metabolic reprogramming contributes to PDAC progression and drug resistance; however, the oncogenic signaling associated with metabolism in chemo-resistant PDAC remains incompletely defined. METHODS: Integrated single-cell transcriptomic analyses combined with bulk RNA sequencing were performed to identify candidate genes associated with metastasis, proliferation, and drug resistance in PDAC, leading to the prioritization of phosphofructokinase-platelet (PFKP), a rate-limiting glycolytic enzyme implicated in tumor metabolic adaptation. Function